Clinical Trials Logo

Virus-HIV clinical trials

View clinical trials related to Virus-HIV.

Filter by:
  • None
  • Page 1

NCT ID: NCT05322083 Not yet recruiting - Virus-HIV Clinical Trials

HIV A6 Genome In ART Unsuccessful Patients On DOR

HIV-A6-DOR
Start date: May 2022
Phase:
Study type: Observational

The aim of the study is to evaluate the efficacy of Doravirine (DOR) in the second-line therapy for patients infected with HIV-1 sub-subtype A6 and its derivatives and having the mutations to previously used drugs

NCT ID: NCT05083273 Completed - Virus-HIV Clinical Trials

Life Experience of People Aged 60 and Over Living With HIV

PVVIH
Start date: May 18, 2021
Phase:
Study type: Observational

The purpose of this study is to Assess the impact of HIV on the life course of patients aged 60 and over.

NCT ID: NCT04772469 Completed - HIV Infections Clinical Trials

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men

Start date: March 22, 2021
Phase: N/A
Study type: Interventional

This is a randomized controlled trial to test a combination behavioral and biomedical interventions to improve the HIV prevention and care cascades in a population of mobile men in a high priority setting (fishermen in Kenya). The intervention strategy is to recruit and train highly socially-connected men to distribute HIV self-tests and provide linkage support to men in their close social networks. The study will determine whether this social network-based approach along with small financial incentives in the form of transport vouchers can increase men's self-testing, linkage to and uptake of ART and PrEP after self-testing, virologic suppression at 6 months (for those initiating ART) and PrEP adherence (for those initiating PrEP) at 6 months. The study includes a longitudinal qualitative and mixed methods (quantitative and qualitative assessments) to identify the pathways of intervention action, and understand how the social network-based approach with support for linkage affects testing and ART and PrEP uptake and retention in men.

NCT ID: NCT04581746 Active, not recruiting - Covid19 Clinical Trials

Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)

coVIHd-19
Start date: November 25, 2020
Phase: N/A
Study type: Interventional

The non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients during COVID-19 epidemic. This change in care can have an impact on follow-up and access to treatment for PVVIH.

NCT ID: NCT04575545 Not yet recruiting - Covid19 Clinical Trials

Prevalence of COVID-19 Infection in a Cohort of Patients Infected by the HIV and Patients Taking PrEP

Start date: October 2020
Phase:
Study type: Observational

The purpose of the study is to assess seroprevalence of COVID-19 infection in a cohort of HIV + patients and in a cohort of patients taking PrEP by emtricitabine / tenofovir.

NCT ID: NCT03671291 Completed - Virus-HIV Clinical Trials

Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV

Start date: April 3, 2019
Phase: N/A
Study type: Interventional

Missed opportunity to pre-exposure prophylaxis is a survey study that will be addressed to newly infected with human immunodeficiency virus (HIV) persons. The purposes of this study is to understand why despite the fact that pre-exposure prophylaxis exist, these persons have been contaminated with HIV.

NCT ID: NCT03195452 Completed - Virus-HIV Clinical Trials

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient

QDISS
Start date: November 8, 2017
Phase: Phase 2
Study type: Interventional

Raltegravir (RAL) is a very effective antiretroviral drug with a favorable long term tolerability. RAL offers many advantages such as lack of drug-drug interactions, a good safety profile particularly on lipids, inflammation and bone parameters. Ral can be an very interesting for patient with comorbidities and comedications, intolerance or toxicities with their current ARV treatment. However its current formulation of one tablet of 400mg twice a day coul not suit many patients. A new once-a-day formulation of RAL has been developed, with two tablets of 600 mg QD. Pharmacokinetic study in healthy volunteers has shown that this dosing provides increased RAL exposure compared to the standard formulation of 400 mg given twice a day. The objective of this study is to evaluate the maintain of virologic suppression with raltegravir 600mg 2 tablets qd as part of a triple antiretroviral regimen in virologically controlled patients.

NCT ID: NCT02898896 Terminated - Virus-HIV Clinical Trials

Coronary Artery Disease (CAD) in Suppressed HIV-infected

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

HIV-infected patients with intermediate-high risk have a high prevalence of CAD and a substantial proportion of obstructive CAD. Degree of stenosis is associated with immunoactivation (lymphocyte and monocyte) and microbial translocation